Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)

2020 ◽  
Vol 52 (5) ◽  
pp. 493-505 ◽  
Author(s):  
Thomas Aparicio ◽  
Florence Canouï-Poitrine ◽  
Philippe Caillet ◽  
Eric François ◽  
Tristan Cudennec ◽  
...  
2019 ◽  
Vol 10 (1) ◽  
pp. 143-148 ◽  
Author(s):  
Natalia Asimakopoulou ◽  
John Souglakos ◽  
Nikolaos Kentepozidis ◽  
Athanasios Karampeazis ◽  
Athanasios Kotsakis ◽  
...  

2020 ◽  
Vol 11 (8) ◽  
pp. 1268-1273
Author(s):  
Camilla Lisanti ◽  
Debora Basile ◽  
Annamaria Parnofiello ◽  
Elisa Bertoli ◽  
Victoria Josephine Andreotti ◽  
...  

2015 ◽  
Vol 26 (3) ◽  
pp. 463-476 ◽  
Author(s):  
D. Papamichael ◽  
R.A. Audisio ◽  
B. Glimelius ◽  
A. de Gramont ◽  
R. Glynne-Jones ◽  
...  

2012 ◽  
Vol 23 ◽  
pp. ix203
Author(s):  
V. Shankaran ◽  
D. Mummy ◽  
L. Koepl ◽  
D. Blough ◽  
Y.M. Yim ◽  
...  

Author(s):  
Ifigenia Konstantinou ◽  
Iestyn M. Shapey ◽  
Demetris Papamichael ◽  
Nicola de Liguori Carino

2020 ◽  
Vol 11 (8) ◽  
pp. 1229-1236
Author(s):  
Marine Gilabert ◽  
Pauline Ries ◽  
Brice Chanez ◽  
Simon Triby ◽  
Eric Francois ◽  
...  

2017 ◽  
Vol 24 (6) ◽  
pp. 390
Author(s):  
A.B.K. Abrahao ◽  
S. Karim ◽  
B. Colwell ◽  
S. Berry ◽  
J. Biagi

In recently published data, the predictive value of primary tumour location for the treatment of metastatic colorectal cancer with available biologic therapies has been explored. Recognizing the potential effect of those data on clinical practice, we convened a meeting of Canadian experts who treat metastatic colorectal cancer to develop a set of national, evidence-based treatment guidelines based on primary tumour location. This report summarizes the relevant evidence and presents the consensus recommendations of those experts. 


2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 8519-8519 ◽  
Author(s):  
E. B. Elkin ◽  
S. Lee ◽  
E. S. Casper ◽  
D. Kissane ◽  
N. E. Kemeny ◽  
...  

8519 Background: Shared decision-making is a tenet of contemporary oncology practice. However, it is uncertain how involved elderly patients want to be in making treatment decisions and how physicians perceive patient preferences for involvement in decision-making. Methods: In structured interviews about multiple facets of chemotherapy treatment decision-making, we asked patients age 70 and older seen at our specialty cancer center with a recent diagnosis of metastatic colorectal cancer (CRC) about their preferences for making treatment decisions. We used Degner’s control preference scale to measure patient preference for decision control. Treating oncologists described their perception of each patient’s preference for decision control using the same scale. Control preference was assessed in relation to socio-demographic characteristics and functional status. Results: Of 52 patients interviewed, the mean age was 76 years (range 70–89), 52% were male, 60% were educated beyond high school and 25% required some help with activities of daily living (ADL). Preferences for involvement in treatment decision-making demonstrated marked variation (Table). Compared with female patients, males expressed a stronger preference for decision control (p<0.05). Preference for decision control was somewhat greater in patients under age 80, those with more education, and those with no ADL impairment, but these associations were not statistically significant. In 26% of cases, the treating physician’s perception and the patient’s expressed preference for decision control were concordant. Conclusions: In older patients with advanced CRC, preference for control in treatment decision-making shows marked heterogeneity and some correlation with socio-demographic characteristics and functional status. Physicians’ perceptions of patient preference for decision control are often inconsistent with patients’ actual preferences. [Table: see text] No significant financial relationships to disclose.


Sign in / Sign up

Export Citation Format

Share Document